The global gene therapy market was valued at USD 3.61 billion in 2019 and is projected to reach USD 35.67 billion by 2027, growing at a robust compound annual growth rate (CAGR) of 33.6%. In 2019, the United States led the global landscape, accounting for 59.83% of the total market share.

The gene therapy market is gaining significant traction globally, driven by the rising prevalence of genetic disorders, advancements in gene-editing technologies, and growing interest in personalized medicine. Gene therapy offers promising solutions for previously untreatable diseases by targeting the root cause at the genetic level. With increasing regulatory approvals and robust investment in research and development, the gene therapy market is poised for substantial growth. Despite challenges such as high treatment costs and regulatory complexities, the market continues to expand across key regions, especially in North America and Asia Pacific. As innovation progresses, the gene therapy market is expected to play a transformative role in the future of healthcare.

Continue reading for more details:

https://www.fortunebusinessinsights.com/industry-reports/gene-therapy-market-100243

Market Segmentation

• By Therapy Type: Includes in vivo gene therapy and ex vivo gene therapy.

• By Vector Type: Categorized into viral vectors (e.g., adenovirus, lentivirus, AAV) and non-viral vectors (e.g., plasmid DNA).

• By Indication: Covers cancer, neurological disorders, cardiovascular diseases, inherited genetic disorders, and others.

• By End User: Divided into hospitals, specialty clinics, and research & academic institutions.

 List Of Key Companies Profiled in Gene Therapy Market:

• Novartis AG

• Spark Therapeutics, Inc.

• Biogen

• Gilead Sciences, Inc

• Amgen, Inc.

• Jazz Pharmaceuticals, Inc.

• Sarepta Therapeutics

• GlaxoSmithKline plc

• Other Prominent Players

Market Growth

• The gene therapy market is witnessing accelerated growth due to rising incidences of genetic disorders and rare diseases.

• Technological advancements in gene editing tools, such as CRISPR and viral vectors, are fueling innovation within the gene therapy market.

• Increasing regulatory approvals and breakthrough designations are creating momentum in the global gene therapy market.

• Expanding investment from pharmaceutical and biotech companies continues to drive expansion of the gene therapy market.

• The growing focus on personalized and precision medicine is further propelling demand within the gene therapy market.

Restraining Factors

• High treatment costs pose a major barrier to access in the gene therapy market.

• Limited manufacturing scalability and supply chain challenges affect consistent therapy availability.

• Stringent regulatory pathways can delay commercialization within the gene therapy market.

• Potential immune responses and long-term safety concerns are factors restraining wider adoption.

• Lack of skilled professionals and infrastructure in developing regions limits the reach of the gene therapy market.

Regional Analysis

• North America leads the gene therapy market due to strong R&D presence, advanced infrastructure, and supportive regulatory frameworks.

• Europe follows closely, benefiting from active clinical trials and strategic government investments.

• Asia Pacific is rapidly emerging in the gene therapy market, driven by increased healthcare spending and growing research activity in countries like China, Japan, and India.

• Latin America and Middle East & Africa represent developing markets with rising interest in gene-based therapies, though growth is moderated by limited infrastructure.

Contact us:

Fortune Business Insights™ Pvt.

Phone: USA: +1 833 909 2966 (Toll-Free),

United Kingdom: +44 808 502 0280 (Toll-Free)

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com